Pfizer shares have plummeted 50% due to a patent cliff and declining revenue from COVID-19 treatments. However, Pfizer is leveraging AI to save costs and improve drug development. The looming patent cliff, with key drugs set to lose patent exclusivity, poses challenges. Pfizer’s acquisition of Metsera for $10 billion could lead to potential blockbuster drugs in the weight loss market. Pfizer’s AI investments have led to significant productivity gains and cost savings. The company’s dividend yield of 6.9% is attractive for income-oriented investors. Pfizer’s early adoption of AI technology positions it well in the pharmaceutical industry.

Read more at Yahoo Finance: This 7% Yielder Could Be a Top AI Play